ToweRx Effervescent Potassium
Generic Name: potassium bicarbonate
Dosage Form: tablet, effervescent
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
DESCRIPTION: An oral potassium supplement. Each effervescent tablet in solution provides 25 mEq of potassium as supplied by 2.4g potassium bicarbonate with 1.4g Citric Acid, FD and C Yellow #6 Dye, FD and C Yellow #6 Lake, Natural Orange Flavor, Polyethylene Glycol, Saccharin, Sodium Benzoate, and Sorbitol.
CLINICAL PHARMACOLOGY: Potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in many essential physiological processes, such as the maintenance of intracellular tonicity, nerve impulse transmission, enzymatic reactions in intermediary metabolism, cardiac, skeletal and smooth muscle function, and the maintenance of normal renal function.
Potassium depletion may occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Potassium depletion usually develops slowly as a result of lengthy therapy with oral diuretics, primary or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion is additionally associated with severe diarrhea, accompanied by vomiting. Potassium depletion due to these causes is usually accompanied by a concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may result in fatigue, weakness, nausea, drowsiness, loss of appetite, edema, oliguria and chronic ileus with distention. Potassium deficiency may be manifested by shallow breathing, lowered blood pressure, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, or other ECG changes, such as lengthened Q-T interval, depressed S-T segment, and depressed or inverted T-wave. In advanced cases of potassium deficiency, flaccid paralysis and/or impaired ability to concentrate urine may be evident.
1. For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in digitalis intoxication and in patients with hypokalemic familial
2. For prevention of potassium depletion when the dietary intake of potassium is inadequate in the following conditions; patients receiving digitalis and
diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassium-losing
nephropathy, and certain diarrheal states.
3. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a
normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with
potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be
Hyperkalemia occurs infrequently in patients with normal renal function who receive oral potassium supplements. The following are symptoms of hyperkalemia: mental confusion, unexplained anxiety, cardiac arrhythmias, numbness or tingling in lips, feet, or hands, difficult breathing or shortness of breath, weakness or heaviness of legs, and unusual fatigue or weakness. (See Contraindications, Warnings, and Overdosage).
The focus of the treatment of severe hyperkalemia should be on the reduction of the serum potassium level by furthering the transfer of potassium from the extracellular to the intracellular space. The treatment may include the following: a) intravenous administration of 1 liter of a `0 percent glucose solution which contains 20 to 40 units of insulin; b) in the acidolic patient, 150 mEq to 300 mEq of sodium bicarbonate administered intravenously. Other actions should include the discontinuing of potassium-sparing diuretics and potassium-containing drugs and often the oral use of a cations exchange resin (such as sodium polystyrene sulfonate) in order to eliminate gastrointestinal potassium. To make sure that the resin moves rapidly through the gastrointestinal tract, a nonabsorbable polyhydric alcohol such as sorbitol should be administered in sufficient amounts to cause a soft to semiliquid bowel movement to occur every few hours.
Hemodialysis can also be used as an effective alternative means to remove excess potassium.
Boxes of 30, 100, and 250 tablets.
|ToweRx Effervescent Potassium
potassium bicarbonate tablet, effervescent
|Labeler - Tower Laboratories Ltd (001587203)|
|Tower Laboratories Ltd||001587203||manufacture|